COMMUNIQUÉS West-GlobeNewswire

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
24/02/2026
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting [...]
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
24/02/2026
Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophy HOPE-3 clinical study report (CSR) submitted to the U.S. Food and Drug Administration (FDA) in [...]
Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana
24/02/2026
Center to Create Local Jobs and Strengthen U.S. Healthcare Supply Resilience SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing [...]
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
24/02/2026
- Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength [...]
TAP Sleep Care Groundbreaking Dual Therapy: Mouth Shield + TAP Improves Oral, Cardiac, and Cognitive Health in OSA
24/02/2026
DALLAS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- TAP Sleep Care , powered by Airway Management, today highlights groundbreaking clinical research on the benefits of dual therapy using the patented Mouth Shield with TAP devices [...]
OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers
24/02/2026
MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic data licensing agreement with [...]
Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
24/02/2026
Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS’s fingerprint drug testing technology NEW YORK [...]
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
24/02/2026
CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the [...]
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
24/02/2026
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine as third-line therapy [...]
CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals
24/02/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 24, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement issued this morning by Sarborg Limited regarding the [...]
ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera
24/02/2026
Technology supports the evolution of enteral access from blind procedures to real-time visualized placement TYLER, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or [...]
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
24/02/2026
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release constitutes a “ [...]
Apogee Therapeutics to Participate in Upcoming March Conferences
24/02/2026
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health [...]
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
24/02/2026
Jeito Capital, Novo Holdings and other healthcare investors join Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds Additional capital further supports clinical development of ALV [...]
Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract
24/02/2026
First of two Pivotal Efficacy Studies support future sNDA submission for Treatment of Pulmonary Anthrax Oral NUZYRA Tablets Produced in the U.S. as a Result of the Company's Onshoring Initiative were Procured by BARDA [...]
Glass House Brands Board of Directors Establishes Product Expansion Committee to Support New Product and Business Development
24/02/2026
LONG BEACH, Calif. and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Porosome Therapeutics Announces New Porosome-Targeted Medicines Developed Using AI
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the development of novel first-in-class porosome-targeting small molecules and blood brain barrier (BBB) [...]
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
24/02/2026
Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarter Full year 2025 revenue of $738 million, a year-over-year increase of 16 [...]
Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity
24/02/2026
Data presented at 16 th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based platform to optimise cis-bispecific antibody-drug conjugate (ADC) discovery [...]

Pages